We are live on ! Find out more
ZLAB icon

Zai Lab

21.03 USD
-0.89
4.06%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
21.03
0.00
0%
1 day
-4.06%
5 days
-12.96%
1 month
-16.15%
3 months
-19.18%
6 months
11.8%
Year to date
21.35%
1 year
4.06%
5 years
-71.45%
10 years
-24.7%
 

About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Employees: 1,797

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 15%
Neutral 85%
Negative 0%
Neutral
Seeking Alpha
2 days ago
Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
I initiate Zai Lab at Buy with a $43 target; the China franchise provides a floor, while Zoci's global potential is underappreciated. ZLAB's China business faces price cuts and ZEJULA competition, but sequential product revenue growth and management's 2027 growth outlook suggest stabilization. Zoci's early SCLC and epNEC data support a potential global oncology re-rating, with epNEC topline results and a possible U.S. BLA in 2027.
Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
Positive
Seeking Alpha
4 days ago
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
Zai Lab looks underappreciated as the wholly owned developer of zoci, a potential DLL3 treatment backbone, rather than merely a China distributor. Amgen and Boehringer are funding zoci combination studies; first-line data showed an 81.8% response rate across 33 evaluable patients. I estimate roughly ten quarters of debt-adjusted cash runway at elevated trial spending, while management expects product revenue growth to return in 2027.
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
Neutral
Business Wire
7 days ago
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly.
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
Neutral
Business Wire
7 days ago
Zai Lab Announces Participation in Investor Conferences in November 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in November 2026: UBS Global Biopharma Conference Date: November 17, 2026 Event Format: 1-on-1 meetings only Location: London, UK Jefferies Global Healthcare Conference in London Date: November 18 and 19, 2026 Fireside Chat: Wednesday, November 18, 2026 at 10:30AM GMT Event Format: Pre.
Zai Lab Announces Participation in Investor Conferences in November 2026
Positive
Benzinga
7 days ago
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis.
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
Neutral
Seeking Alpha
7 days ago
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Neutral
Business Wire
7 days ago
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scien.
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
Positive
Zacks Investment Research
10 days ago
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
Neutral
MarketBeat
14 days ago
Zai Lab Q3 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
Zai Lab Q3 Earnings Call Highlights
Neutral
Seeking Alpha
15 days ago
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™